Please provide your email address to receive an email when new articles are posted on . The Hadassah Self-Visual Acuity Screener demonstrated high reliability, accuracy and alignment with standard ...

Patients with infantile nystagmus had significant gains in near and distance visual acuity as well as stereopsis following regular sessions of vision training with RevitalVision software, according to ...

The U.S. Food and Drug Administration has approved Yuvezzi (carbachol and brimonidine tartrate) ophthalmic solution 2.75%/0.1 ...

Yuvezzi, a combination cholinergic agonist and alpha-adrenergic agonist, is now FDA-approved as a once-daily treatment for ...

The Companies plan to file an application with the FDA in the second half of 2025. Topline data were announced from a phase 3 trial evaluating MR-141 (phentolamine ophthalmic solution 0.75%) for the ...

BRIMOCHOL™ PF met its prespecified FDA primary endpoint for binocular near visual acuity across multiple time points, starting at hour 1, versus active controls, and was well-tolerated with no ...

Up to 19% of prevalent dementia cases may be attributable to impaired vision, a cross-sectional analysis suggested. Contrast sensitivity impairment showed the strongest relationship, followed by near ...

Tenpoint Therapeutics announced FDA’s approval of Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% ...